Back to search

Article

Antigen-Presenting B-Cell Signature Predicts Response and Survival in HER2-Positive Breast Cancer

2026-05-12

Abstract excerpt

<title>Abstract</title> <p>Neoadjuvant therapy (NAT) with HER2-targeted agents is the standard treatment for patients with HER2-positive early breast cancer (HER2 + EBC). Although high levels of tumor-infiltrating lymphocytes (TILs) are associated with higher pathologic complete response (pCR) rates and improved recurrence-free survival (RFS), the specific immune components responsible remain unclear. In this stu...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
4718ebd8-dccf-5bca-bbff-937da2c1288e
DOI
10.21203/rs.3.rs-9236222/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Antigen-Presenting B-Cell Signature Predicts Response and Survival in HER2-Positive Breast CancerDOI 10.21203/rs.3.rs-9236222/v1
Novel Immune Subtypes Identification of HER2 Positive Breast Cancer Based On Immunogenomic LandscapeSemantic proximity
Anti-HER2 CD4(+) T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer.Semantic proximity
Multiomic dissection of HR <sup>+</sup> /HER2 <sup>−</sup> invasive lobular breast carcinoma reveals mobilized yet dysfunctional anti-tumor immunity shaped by tumor-stroma crosstalk and impaired antigen presentationSemantic proximity
Molecular intrinsic subtypes, genomic and immune landscapes of BRCA-proficient but HRD-high ER-positive/HER2-negative early breast cancersSemantic proximity
Identification of immune-related biomarkers for predicting neoadjuvant chemotherapy sensitivity in HER2 negative breast cancer via bioinformatics analysisSemantic proximity
Immune Effective Score As A Predictor Of Response To Neoadjuvant Trastuzumab Therapy And A Prognostic Indicator For HER2-positive Breast CancerSemantic proximity
Genomic and transcriptomic profiles associated with response to eribulin and nivolumab combination in HER-2-negative metastatic breast cancer.Semantic proximity
Molecular intrinsic subtypes, genomic, and immune landscapes of BRCA-proficient but HRD-high ER-positive/HER2-negative early breast cancersSemantic proximity
Identification of A 10-Gene Signature To Predict Efficacy of Neoadjuvant Therapy in Patients With HER2 Positive Breast Cancer.Semantic proximity
A novel immune subtype classification of ER-positive, PR-negative and HER2-negative breast cancer based on the genomic and transcriptomic landscapeSemantic proximity
Peripheral blood gene expression signatures of systemic immunity predict tumor microenvironment biology and therapeutic response in breast cancerSemantic proximity
An estrogen receptor signaling transcriptional program linked to immune evasion in human hormone receptor-positive breast cancerSemantic proximity
Select a neighboring publication to make it the new centre.